Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 16;9(6):233.
doi: 10.3390/biom9060233.

IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy

Salvador Resino  1 , María A Navarrete-Muñoz  2   3 , Julià Blanco  4 , Yolanda M Pacheco  5 , Iván Castro  6 , Juan Berenguer  7 , Jesús Santos  8   9 , Francisco J Vera-Méndez  10 , Miguel Górgolas  11 , M A Ángeles Jiménez-Sousa  12 , José M Benito  13   14 , Norma Rallón  15   16 ; CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network Project RIS/EPICLIN 10_2015  17
Affiliations

IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy

Salvador Resino et al. Biomolecules. .

Abstract

Interleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism is related to CD4+ recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count <200 cells/mm3. We performed a retrospective study in 411 patients followed for 24 months with a DNA sample available for genotyping. The change in CD4+ T-cells count during the follow-up was considered as the primary outcome. The rs6897932 polymorphism had a minimum allele frequency (MAF) >20% and was in Hardy-Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while 155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides, rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up ≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini-Hochberg), only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the management of HIV-infected patients starting cART with CD4+ T-cells count <200 cells/mm3.

Keywords: CD4; HIV; IL7RA; SNPs; cART; immune reconstitution.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagram of inclusion criteria of patients. This picture shows the inclusion criteria and the sequential strategy of selection of patients included in the study. “n” indicates the number of patients selected after each step during filtering process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Panel de Expertos de Gesida y Plan Nacional sobre el Sida National consensus document by gesida/national aids plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (january 2011 update) Enferm. Infecc. Microbiol. Clin. 2011;29:209.e1-103. - PubMed
    1. Thompson M.A., Aberg J.A., Hoy J.F., Telenti A., Benson C., Cahn P., Eron J.J., Gunthard H.F., Hammer S.M., Reiss P., et al. Antiretroviral treatment of adult hiv infection: 2012 recommendations of the international antiviral society-USA panel. JAMA. 2012;308:387–402. doi: 10.1001/jama.2012.7961. - DOI - PubMed
    1. Kelley C.F., Kitchen C.M., Hunt P.W., Rodriguez B., Hecht F.M., Kitahata M., Crane H.M., Willig J., Mugavero M., Saag M., et al. Incomplete peripheral CD4+ cell count restoration in hiv-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 2009;48:787–794. doi: 10.1086/597093. - DOI - PMC - PubMed
    1. Helleberg M., Kronborg G., Larsen C.S., Pedersen G., Pedersen C., Obel N., Gerstoft J. Poor CD4 response despite viral suppression is associated with increased non-aids-related mortality among HIV patients and their parents. AIDS. 2013;27:1021–1026. doi: 10.1097/QAD.0b013e32835cba4c. - DOI - PubMed
    1. Baker J.V., Peng G., Rapkin J., Krason D., Reilly C., Cavert W.P., Abrams D.I., MacArthur R.D., Henry K., Neaton J.D. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for aids and non-aids diseases. J. Acquir. Immune Defic. Syndr. 2008;48:541–546. doi: 10.1097/QAI.0b013e31817bebb3. - DOI - PMC - PubMed

Publication types

Substances